EdiTy Therapeutics

Chameleon Biosciences

This company develops immune-evading gene therapy delivery platforms for pharmaceutical firms and patients with genetic disorders.

Immitra Bio

This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.

Epitome Therapeutics

This biotechnology firm develops an epigenome editing platform for programmable gene expression to treat patients with rare genetic and metabolic disorders.

Aera Therapeutics

This biotechnology company develops delivery platforms for genetic medicines to treat various diseases for biopharmaceutical partners and patients.

Alia Therapeutics

The company develops gene editing medicines for patients with genetic diseases.

Replay Therapeutics

This biotech company develops genome writing and delivery platforms to provide genetic medicines for patients with rare skin, eye and haematological diseases.

EDITAS Medicine

The company develops CRISPR-based genome editing medicines to treat patients with serious genetic diseases, including blood disorders and inherited eye conditions.

Modulari-T Biosciences

This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.